The porphyrias: Clinical presentation, diagnosis and treatment

European Journal of Dermatology

Volumn 16, Issue 3, 2006, Pages 230-240

  Poblete Gutierrez P ^a   Wiederholt, T ^b   Merk, H F ^b   Frank, J ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Acute porphyrias; Acute porphyric attack; Photosensitivity; Porphyria; Porphyrinogenic drugs

Indexed keywords

CHLOROQUINE; HEME ARGINATE; PORPHYRINOGEN;

ACUTE INTERMITTENT PORPHYRIA; BLOOD EXAMINATION; CONGENITAL ERYTHROPOIETIC PORPHYRIA; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FECES ANALYSIS; GENE MUTATION; HEPATOERYTHROPOIETIC PORPHYRIA; HUMAN; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; REVIEW; URINALYSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; PORPHYRIAS;

EID: 33646691020     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Bickers DR, Frank J. The porphyrias. In: Fitzpatrick TB, Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Dermatology in general medicine, edition 6. McGraw Hill, 2003: 1435-66.
2. de Verneuil H, Aitken G, Nordmann Y. Familial and sporadic porphyria cutanea: two different diseases. Hum Genet 1978; 44: 145-51.
3. Elder GH, Roberts AG, de Salamanca RE. Genetics and pathogenesis of human uroporphyrinogen decarboxylase defects. Clin Biochem 1989; 22: 163-8.
4. Poblete-Gutierrez P, Mendez M, Wiederholt T, Merk HF, Fontanellas A, Wolff C, Frank J. The molecular basis of porphyria cutanea tarda in Chile: identification and functional characterization of mutations in the uroporphyrinogen decarboxylase gene. Exp Dermatol 2004; 13: 372-9.
5. Elder GH. Human URO-D defects. In: Orfanos CE, Stadler R, Gollnick H, eds. Dermatology in five continents. Berlin: Springer-Verlag, 1988: 857-60.
6. Kolanko E, Bickle K, Keehn C, Glass LF. Subepidermal blistering disorders: a clinical and histopathologic review. Semin Cutan Med Surg 2004; 23: 10-8.
7. Brady JJ, Jackson HA, Roberts AG, Morgan RR, Whatley SD, Rowlands GL, Darby C, Shudell E, Watson R, Paiker J, Worwood MW, Elder GH. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000; 115: 868-74.
8. Armas R, Krause P, Wolff C. Porphyria cutanea tarda, chronic liver disease caused by the C virus and hepatocarcinoma. Clinical case. Rev Med Chil 1994; 122: 72-4.
9. Cox TM. Erytthropoietic protoporphyria. J Inherit Metab Dis 1997; 20: 258-69.
10. Lecha M. Erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 2003; 19: 142-6.
11. Frank M, Doss OD. Severe liver disease in protoporphyria. In: Vermeer BJ, Wuepper KD, van Vloten WA, Baart de la Faille H, van der Schoroeff JG, eds. Curr Probl Dermatol, Volume 20. Karger, 1991: 160-7.
12. Mercurio MG, Prince G, Weber FL, Jacobs G, Zaim MT, Bickers DR. Terminal hepatic failure in erythropoietic protoporphyria. J Am Acad Dermatol 1993; 29: 829-33.
13. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Med 2002; 30: 27-8.
14. Navarro S, Del Hoyo P, Campos Y, Abitbol M, Moran-Jimenez MJ, Garcia-Bravo M, Ochoa P, Grau M, Montagutelli X, Frank J, Garesse R, Arenas J, de Salamanca RE, Fontanellas A. Increased mitochondrial respiratory chain enzyme activities correlate with minor extent of liver damage in mice suffering from erythropoietic protoporphyria. Exp Dermatol 2005; 14: 26-33.
15. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol 2002; 117: 779-95.
16. Fritsch C, Lang K, Bolsen K, Lehmann P, Ruzicka T. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 1998; 11: 347-57.
17. Tsai SF, Bishop DF, Desnick RJ. Coupled-enzyme and direct assays for uroporphyrinogen III synthase activity in human erythrocytes and cultured lymphoblasts. Enzymatic diagnosis of heterozygotes and homozygotes with congenital erythropoietic porphyria. Anal Biochem 1987; 166: 120-33.
18. Elder GH, Roberts AG. Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 1995; 27: 207-14.
19. Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B 2001; 64: 93-8.
20. Poblete Gutiérrez P, Kunitz O, Wolff C, Frank J. Diagnosis and treatment of the acute porphyrias: An interdisciplinary challenge. Skin Pharmacol Appl Skin Physiol 2001; 14: 393-400.
21. Doss M, von Tiepermann R, Schneider J, Schmid H. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 1979; 57: 1123-7.
22. Crimlisk HL. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 1997; 62: 319-28.
23. Moore MR, Hift RJ. Drugs in the acute porphyrias: Toxicogenetic diseases. Cell Mol Biol 1997; 43: 89-94.
24. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142: 439-50.
25. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 2002; 48: 1891-900.
26. Frank J, Christiano AM. Variegate porphyria: past, present and future. Skin Pharmacol Appl Skin Physiol 1998; 11: 310-20.
27. Deybach JC, da Silva V, Grandchamp B, Nordmann Y. The mitochondrial location of protoporphyrinogen oxidase. Eur J Biochem 1995; 149: 431-5.
28. Martasek P. Hereditary coproporphyria. Semin Liver Dis 1998; 18: 25-32.
29. Holmann JR, Green JB. Acute intermittent porphyria. More than just abdominal pain. Postgrad Med 1989; 86: 295-8.
30. Kauppinen R. Porphyrias. Lancet 2005; 365: 241-52.
31. Grandchamp B, Puy H, Lamoril J, Deybach JC, Nordmann Y. Review: molecular pathogenesis of hepatic acute porphyrias. Gastroenterol Hepatol 1996; 11: 1046-52.
32. Frank J, Christiano AM. The genetic bases of the porphyrias. Skin Pharmacol Appl Skin Physiol 1998; 11: 297-309.
33. Sarkany RPE. The management of porphyria cutanea tarda. Clin Exp Dermatol 2001; 26: 225-32.
34. Stölzel U, Köstler E, Schuppan D, Richter M, Wollina U, Doss MO, Wittekind C, Tannapfel A. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 2003; 139: 309-13.
35. Thunell S, Harper P, Brock A, Petersen NE. Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scand J Clin Lab Invest 2000; 60: 541-59.
36. Dhar GJ, Bossenmaier I, Petryka ZJ, Cardinal R, Watson CJ. Effects of hematin in hepatic porphyria. Further studies. Ann Intern Med 1975; 83: 20-30.
37. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med 1986; 315: 235-8.
38. Tenhunen R, Mustajoki P. Acute porphyria: treatment with heme. Semin Liver Dis 1998; 18: 53-5.
39. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993; 153: 2004-8.
40. Da Silva V, Simonin S, Deybach JC, Puy H, Nordmann Y. Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 1995; 238: 163-8.